TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
TScan Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -1695.1%. For fiscal 2025 it was -1315.4%, against -4787.7% the year before. The highest annual figure on record is -444.0% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1315.4% | +3472.3 |
| FY2024 | Dec 31, 2024 | -4787.7% | −4343.7 |
| FY2023 | Dec 31, 2023 | -444.0% | +48.3 |
| FY2022 | Dec 31, 2022 | -492.3% | −12.7 |
| FY2021 | Dec 31, 2021 | -479.6% | +1938.1 |
| FY2020 | Dec 31, 2020 | -2417.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -2901.3% | −1644.7 |
| Q1 FY2026 | Mar 31, 2026 | -2967.3% | −1297.6 |
| Q4 FY2025 | Dec 31, 2025 | -929.4% | +4591.2 |
| Q3 FY2025 | Sep 30, 2025 | -1475.6% | +1634.2 |
| Q2 FY2025 | Jun 30, 2025 | -1256.6% | +5108.0 |
| Q1 FY2025 | Mar 31, 2025 | -1669.7% | +3873.2 |
| Q4 FY2024 | Dec 31, 2024 | -5520.6% | −5224.4 |
| Q3 FY2024 | Sep 30, 2024 | -3109.8% | −2473.1 |
| Q2 FY2024 | Jun 30, 2024 | -6364.6% | −5582.8 |
| Q1 FY2024 | Mar 31, 2024 | -5542.9% | −5208.6 |
| Q4 FY2023 | Dec 31, 2023 | -296.2% | +306.4 |
| Q3 FY2023 | Sep 30, 2023 | -636.7% | −143.7 |
| Q2 FY2023 | Jun 30, 2023 | -781.8% | −405.9 |
| Q1 FY2023 | Mar 31, 2023 | -334.3% | +200.7 |
| Q4 FY2022 | Dec 31, 2022 | -602.6% | −104.9 |
| Q3 FY2022 | Sep 30, 2022 | -493.0% | +163.8 |
| Q2 FY2022 | Jun 30, 2022 | -375.9% | −0.9 |
| Q1 FY2022 | Mar 31, 2022 | -535.0% | −144.4 |
| Q4 FY2021 | Dec 31, 2021 | -497.6% | +484.8 |
| Q3 FY2021 | Sep 30, 2021 | -656.8% | +1816.0 |
| Q2 FY2021 | Jun 30, 2021 | -375.0% | – |
| Q1 FY2021 | Mar 31, 2021 | -390.6% | – |
| Q4 FY2020 | Dec 31, 2020 | -982.4% | – |
| Q3 FY2020 | Sep 30, 2020 | -2472.8% | – |
See a number that looks wrong?